{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:43:41Z","timestamp":1792453421156,"version":"4.5.0"},"reference-count":33,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head-to-head randomised trials or real-world studies comparing the safety and efficacy of natalizumab and anti-CD20 monoclonal antibodies are limited. This study aimed to compare the effectiveness and safety of natalizumab versus ocrelizumab\/rituximab in a real-world cohort of relapsing-remitting multiple sclerosis (RRMS) patients using data from the Middle East and North Africa Committee for the Treatment and Research in Multiple Sclerosis (MENACTRIMS) registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This registry-based, retrospective, multicentre study was carried out in seven Middle Eastern countries by analysing data from the MENACTRIMS registry. All adults RRMS patients treated with natalizumab, rituximab or ocrelizumab and maintained on treatment for at least 12 months were included. Patients were matched using propensity scores. Primary outcomes were annualised relapse rate (ARR), confirmed disability progression and improvement and MRI activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1954 patients met the inclusion criteria, with 1277 receiving anti-CD20 therapy (768 on rituximab and 509 on ocrelizumab) and 677 natalizumab. Natalizumab significantly reduced ARR compared with anti-CD20 therapies (0.062 vs 0.092, p=0.001). Confirmed disability progression rates, MRI outcomes and no evidence of disease activity (NEDA-3) were similar between the two groups. However, natalizumab demonstrated higher rates of disability improvement compared with anti-CD20 therapies (9.3% vs 5.5%, p=0.03). Adverse events were more frequent in the anti-CD20 group (36.4% vs 27.5% for natalizumab, p=0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large, real-world cohort, natalizumab was associated with lower ARR, greater likelihood of disability improvement, lesser adverse events, but lower persistence compared with anti-CD20 therapies. These findings provide valuable insights into the comparative efficacy and safety of these RRMS therapies, aiding clinicians in personalised treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335704","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:20:20Z","timestamp":1748784020000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study"],"prefix":"10.1136","volume":"97","clinical-trial-number":[{"clinical-trial-number":"nct05758831","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04578639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04688788","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bassem","family":"Yamout","sequence":"first","affiliation":[{"name":"Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[{"name":"Amiri Hospital, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Frouk Ahmed","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Neurology, Ibn Sina Hospital, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram M","family":"Al-Mahdawi","sequence":"additional","affiliation":[{"name":"Baghdad Medical City Teaching Hospital, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-6063","authenticated-orcid":false,"given":"Samia Joseph","family":"Khoury","sequence":"additional","affiliation":[{"name":"Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"El Ayoubi","sequence":"additional","affiliation":[{"name":"Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[{"name":"MS Department, Rashid Hospital and Dubai Medical College, Dubai Helath authority, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabir","family":"Alkhaboori","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Royal Hospital, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Medicine, College of Medicine and Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-3797","authenticated-orcid":false,"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[{"name":"Department of Neurology, Razi Hospital, Faculty of Medicine of Tunis, University Tunis el Manar, Manouba, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Aljarallah","sequence":"additional","affiliation":[{"name":"King Saud University, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha","family":"Alkhawajah","sequence":"additional","affiliation":[{"name":"King Saud University, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"Department of Neurology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraj","family":"Makkawi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences College of Applied Medical Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Khojah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences College of Applied Medical Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghrid","family":"El-Hajj","sequence":"additional","affiliation":[{"name":"Lebanese University Faculty of Medical Sciences, Dekwaneh, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Massouh","sequence":"additional","affiliation":[{"name":"Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"AlSalamat","sequence":"additional","affiliation":[{"name":"Al-Balqa Applied University Faculty of Medicine, As-Salt, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Dimassi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese American University, Byblos, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Al-Hajje","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Lebanese University, Hadath, Lebanon"},{"name":"National Institute of Public Health, Clinical Epidemiology and Toxicology (INSPECT-LB), Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Lebanese University, Hadath, Lebanon"},{"name":"National Institute of Public Health, Clinical Epidemiology and Toxicology (INSPECT-LB), Beirut, Lebanon"},{"name":"School of Medicine, Lebanese American University, Byblos, Lebanon"},{"name":"Department of Primary Care and Population Health, University of Nicosia Medical School, 2417, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Boumediene","sequence":"additional","affiliation":[{"name":"Inserm U1094, IRD U270, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-5609","authenticated-orcid":false,"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lebanese American University, Byblos, Lebanon"},{"name":"Inserm U1094, IRD U270, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"2026041508350830000_97.5.398.1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646485"},{"key":"2026041508350830000_97.5.398.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8594-9"},{"key":"2026041508350830000_97.5.398.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.03.001"},{"key":"2026041508350830000_97.5.398.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026041508350830000_97.5.398.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2026041508350830000_97.5.398.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"2026041508350830000_97.5.398.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003739"},{"key":"2026041508350830000_97.5.398.8","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/acn3.51130","article-title":"Improving risk-stratification of natalizumab-associated PML","volume":"8","author":"Tugemann","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2026041508350830000_97.5.398.9","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026041508350830000_97.5.398.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"key":"2026041508350830000_97.5.398.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2026041508350830000_97.5.398.12","unstructured":"Organization WH . WHO endorses landmark public health decisions on essential medicines for multiple sclerosis. 2023. Available: https:\/\/www.who.int\/news\/item\/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosis"},{"key":"2026041508350830000_97.5.398.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"2026041508350830000_97.5.398.14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"2026041508350830000_97.5.398.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331"},{"key":"2026041508350830000_97.5.398.16","doi-asserted-by":"crossref","first-page":"9084759","DOI":"10.1155\/2018\/9084759","article-title":"Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study","volume":"2018","author":"Yamout","year":"2018","journal-title":"J Immunol Res"},{"key":"2026041508350830000_97.5.398.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS One"},{"key":"2026041508350830000_97.5.398.18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026041508350830000_97.5.398.19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz445"},{"key":"2026041508350830000_97.5.398.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.010"},{"key":"2026041508350830000_97.5.398.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu194"},{"key":"2026041508350830000_97.5.398.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2026041508350830000_97.5.398.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb20235.x"},{"key":"2026041508350830000_97.5.398.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06838-1"},{"key":"2026041508350830000_97.5.398.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"2026041508350830000_97.5.398.26","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211000280"},{"key":"2026041508350830000_97.5.398.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34627","article-title":"Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis","volume":"4","author":"Hou","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026041508350830000_97.5.398.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06608-z"},{"key":"2026041508350830000_97.5.398.29","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acn3.52118","article-title":"A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","volume":"11","author":"Iaffaldano","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026041508350830000_97.5.398.30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/acn3.51111","article-title":"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"2026041508350830000_97.5.398.31","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221142924"},{"key":"2026041508350830000_97.5.398.32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026041508350830000_97.5.398.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30007-8"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:35:28Z","timestamp":1776267328000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jnnp-2024-335704"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335704","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}